Guardant Health Inc. (GH)
Why Guardant Health Stock Just Crashed 10%
Guardant Health announced plans to sell stock and raise $400 million in new cash. Guardant burned through nearly $300 million over the past year, so the new fund raise should cover about 16 months of cash burn.
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Wood added to her positions in Ibotta, Roblox, and Guardant Health on Thursday. Ibotta has taken a hit after its first two quarters as a public company.
Guardant Health (GH) Recently Broke Out Above the 20-Day Moving Average
After reaching an important support level, Guardant Health (GH) could be a good stock pick from a technical perspective. GH surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.
Guardant Health, Inc. (GH) Q2 2024 Earnings Call Transcript
Guardant Health, Inc. (NASDAQ:GH ) Q2 2024 Results Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Zarak Khurshid - Vice President of Investor Relations Helmy Eltoukhy - Chairman and co-Chief Executive Officer AmirAli Talasaz - Co-Chief Executive Officer Michael Bell - Chief Financial Officer Conference Call Participants Mark Massaro - BTIG Daniel Brennan - TD Cowen Puneet Souda - Leerink Partners Tejas Savant - Morgan Stanley Bill Bonello - Craig-Hallum Jack Meehan - Nephron Research Daniel Arias - Stifel Financial Doug Schenkel - Wolfe Research Patrick Donnelly - Citigroup Tycho Peterson - Jefferies Operator Good afternoon. Thank you for attending today's Guardant Health Q2 2024 Earnings Call.
Guardant Health (GH) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Guardant Health (GH) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Guardant Health (GH) Reports Q2 Loss, Tops Revenue Estimates
Guardant Health (GH) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $0.67 per share a year ago.
What Analyst Projections for Key Metrics Reveal About Guardant Health (GH) Q2 Earnings
Beyond analysts' top -and-bottom-line estimates for Guardant Health (GH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.
Guardant Health's stock up after FDA approves its blood test for colon-cancer screening
Guardant Health Inc.'s stock rose 2.4% Monday, after the company said the Food and Drug Administration has approved its blood test for colon-cancer screening in adults 45 and older who are at average risk for the disease.
Guardant Health (GH) Moves 6.9% Higher: Will This Strength Last?
Guardant Health (GH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Guardant Health Gets FDA Nod on Colorectal Cancer Blood Test
Guardant Health (GH) on Monday said that its Shield colorectal cancer-screening blood test has received approval from the U.S. Food and Drug Administration (FDA), sending shares higher.
FDA Greenlights Guardant Health's Shield Blood Test, Analyst Cautious on Adoption
On Monday, the FDA approved Guardant Health Inc.'s GH Shield blood test for colorectal cancer (CRC) screening in adults age 45 and older who are at average risk for the disease.
Guardant Health Shares Rise 7% After FDA Approves Its Blood Test For Colon Cancers
Shares of Guardant Health jumped 7% on Monday, after the Food and Drug Administration approved the company's blood test to screen for colon cancer, a new testing method the company said is intended to boost the rate of screenings for the disease as fewer eligible Americans opt for colonoscopies.
